Merck’s Phase III KEYNOTE-B96 trial shows significant overall and progression-free survival gains with Keytruda plus ...

Decision follows underwhelming Phase II results from GALAXIES Lung-201 and H&N-202 trials, prompting iTeos and GSK to end ...

In February, the National Institutes of Health (NIH) announced a cut of “indirect expenses” in its funding for research ...

The Tufts Center for the Study of Drug Development (Tufts CSDD) is conducting new research aimed at understanding how study ...